Illumina Inc (NASDAQ:ILMN) Director Daniel Bradbury sold 2,100 shares of Illumina stock on the open market in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $171.17, for a total transaction of $359,457.00. Following the transaction, the director now directly owns 12,466 shares of the company’s stock, valued at approximately $2,133,805. Illumina, Inc. (NASDAQ:ILMN) net profit margin is 13.80% and weekly performance is -1.15%. On last trading day company shares ended up $169.38. Analysts mean target price for the company is $176.97. Illumina, Inc. (NASDAQ:ILMN) distance from 50-day simple moving average (SMA50) is 13.53%.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)Director Chang Ho Ahn unloaded 136,193 shares of the stock on the open market in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $0.99, for a total transaction of $134,831.07. Following the completion of the transaction, the director now directly owns 6,813,924 shares in the company, valued at approximately $6,745,785.Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)shares fell -1.36% in last trading session and ended the day on $0.908. Its return on assets is -102.40%. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) quarterly performance is -29.10%.
On May 21, Biogen Idec Inc (NASDAQ:BIIB) EVP Steven Holtzman sold 1,221 shares of Biogen Idec stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $289.15, for a total transaction of $353,052.15. Following the completion of the sale, the executive vice president now directly owns 5,749 shares of the company’s stock, valued at approximately $1,662,323. Biogen Idec Inc (NASDAQ:BIIB) shares moved down -0.65% in last trading session and was closed at $307.97, while trading in range of $306.76 – $312.95. Biogen Idec Inc (NASDAQ:BIIB) year to date (YTD) performance is 10.16%.
Agios Pharmaceuticals Inc (NASDAQ:AGIO) COO John Duncan Higgons unloaded 5,000 shares of the stock on the open market in a transaction dated Friday, June 13th. The shares were sold at an average price of $45.27, for a total value of $226,350.00.Agios Pharmaceuticals Inc (NASDAQ:AGIO) ended the last trading day at $47.27. Company weekly volatility is calculated as 6.22% and price to cash ratio as 9.90. Agios Pharmaceuticals Inc (NASDAQ:AGIO) showed a positive weekly performance of 10.91%.
Portola Pharmaceuticals Inc (NASDAQ:PTLA) EVP John T. Curnutte unloaded 10,000 shares of the company’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $26.00, for a total transaction of $260,000.00. Portola Pharmaceuticals Inc (NASDAQ:PTLA) weekly performance is 12.86%. On last trading day company shares ended up $26.77. Analysts mean target price for the company is $38.50. Portola Pharmaceuticals Inc (NASDAQ:PTLA) distance from 50-day simple moving average (SMA50) is 16.05%.